Q1 update: Novonesis delivers 4% organic sales growth in line with expectations and reports progress on the integration
03 mai 2024 01h57 HE
|
Novozymes A/S
For the first quarter as Novonesis, the company delivers 4% organic sales growth in line with expectations. Novonesis maintains the 2024 outlook of 5-7% organic sales growth with an adjusted EBITDA...
Trading statement Q1 2024
03 mai 2024 01h56 HE
|
Novozymes A/S
Novonesis realized 4% organic sales growth in line with expectations and maintains 2024 outlook. Ester Baiget, President & CEO: “I am pleased with the first quarter organic sales growth of 4%...
Resolutions from the annual shareholders’ meeting 2024
30 avr. 2024 12h02 HE
|
Novozymes A/S
Today an ordinary shareholders’ meeting was conducted. The following resolutions were made:• Approval of the audited Annual Report for 2023• Approval of distribution of profit with payment of an...
Invitation to the annual shareholders’ meeting
08 avr. 2024 09h17 HE
|
Novozymes A/S
The annual shareholders’ meeting will be held on Tuesday April 30, 2024 at 4:00 pm CET at Bella Center, Center Boulevard 5, Denmark. The distribution of profit will be addressed at the meeting and...
Share-based legacy RSU program granted
08 avr. 2024 05h58 HE
|
Novozymes A/S
Share-based legacy RSU program granted Novonesis’ Board of Directors has following the merger with Chr. Hansen Holding A/S (“Chr. Hansen”) today approved the continuation in 2024 of a...
2024 outlook and pro forma financials
21 mars 2024 02h26 HE
|
Novozymes A/S
Novonesis provides outlook for 2024 with expected 5-7% organic sales growth and ~35% adj. EBITDA margin. Pro forma financials disclosed. Ester Baiget, CEO of Novonesis, said: “Today we provide...
Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21
18 mars 2024 10h26 HE
|
Novozymes A/S
Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21 at 9.00am CET. To join the live webcast, please click here. To register and receive access...
Resolutions from the Extraordinary Shareholders’ Meeting 2024
04 mars 2024 11h06 HE
|
Novozymes A/S
Company Announcement no. 10 March 4, 2024Today an extraordinary shareholders’ meeting was conducted. The following resolutions were made: Adoption of Novonesis A/S as secondary name and...
Invitation to an extraordinary shareholders’ meeting of Novozymes A/S
09 févr. 2024 04h00 HE
|
Novozymes A/S
An extraordinary shareholders’ meeting of Novozymes A/S will be held on Monday March 4, 2024 at 4:00 pm CET at Boege Alle 10-12, 2970 Hoersholm, Denmark.
Attachments
...
The Novozymes Report 2023
08 févr. 2024 13h52 HE
|
Novozymes A/S
This annual report has been released subsequent to the approval of the combination of Novozymes and Chr. Hansen on January 29, 2024. The new combined group is called Novonesis. As an annual...